• search
Microbiology Testing Services Microbiology Testing Services

Microbiology Testing Services

We offer pharmaceutical microbiology testing services with a wide range of in vitro assays and infectious models that can be tailored as per customer requirements.

The pharmaceutical microbiology testing service at Aurigene is supported by BSL-2 compliant lab and a dedicated in vivo facility for bacterial and fungal infection murine disease models. Our team has collaborated on numerous anti-bacterial and anti-fungal agent discovery projects with innovator pharma companies. We have a dedicated team of scientists and allied staff with vast experience in anti-infective drug discovery projects. We have established in vitro assays and in vivo murine efficacy models.       

We also support generic product filings through bioequivalance studies of in vitro time-kill kinetics against reference drug.

Speak to our experts

In vitro Pharmaceutical Microbiology Testing Services

  • Pharmacodynamic studies:   Drug-organism interaction
  • MIC and MBC:   Susceptibility indicators; major parameters used to quantify the activity of an antibacterial agent against the target pathogen
  • Time kill kinetics:   Information on the time course and rate of antimicrobial activity
  • PAE and PA-SME:   Information on persistent effects of antibacterial agents
  • Others:   Antimicrobial combination/effect of serum proteins on MIC/ biofilm studies

In vivo Pharmaceutical Microbiology Testing Services

  • Systemic infection models:   Acute lethal model to generate POC and determine ED50 - primary screening
  • Respiratory tract infection models:   Test efficacy of NCEs in highly vascularized tissue like lungs
  • Thigh infection models:   Test efficacy of NCEs in poorly vascularized tissues like thighs
  • Urinary tract infection models:   Testability of NCEs to clear UTIs
  • Organ burden models:   Testability of NCEs to clear the disseminated infection

Why Aurigene Pharmaceutical Services?

Submissions to the US FDA

Highly qualified & experienced scientists

Audited by the US FDA with Zero 483 in 2019

BSL-2 compliant microbiology lab

Wide range of infectious models & microbiology assay capabilities

Virtual Tour

 

Connect with our scientific experts for your drug discovery, development, and manufacturing needs

We understand that clear communication is essential to successful collaborations, and that's why we have a dedicated team that is always ready to help you. Whether you have questions about our services, want to discuss a potential partnership, or simply want to learn more about our company, we're here to help.

Our team of experts is dedicated to providing personalised solutions tailored to your unique needs. So, please don't hesitate to reach out to us. We look forward to hearing from you and helping you achieve your business goals.

Country

section

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

rightCaptcha

Neoantigen Specific T cells For Cancer Immunotherapy

Neoantigen Specific T cells For Cancer Immunotherapy

An effective anti-tumor immune response in human is marked by presence of T cells reactive against neoantigens. Neoantigens are HLA-bound unique peptides arise from tumor-specific somatic mutations. Neoantigens are highly immunogenic because they are not present in normal tissues and hence bypass central thymic tolerance. The success of immune checkpoint blockade...

Read More

Physiochemical Characterization Services

Backed by our strong chemistry, we enable “Finger-print” protein structure and functional characterization for proteins from naked proteins to hyperglycosylated or derivatized proteins. ...

Read More

Fixed Dose Combination Formulation

Introduction: A fixed dose combination (FDC) includes two or more active pharmaceutical ingredients (APIs) combined in a single dosage form. Fixed dose combination (FDC) product is expected to provide below advantages: Improved medication compliance by reducing the pill burden of patients. To achieve synergistic activity If combinations include doses of each drug...

Read More

Synthesis of 2-hydroxy-3-alkyl-2-phenyl-2,3- dihydroquinazolin-4(1H)-one via molybdenum hexacarbonyl mediated CO gas- and ligand free carbonylative reactions

2016

Carbon monoxide gas and ligand-free conditions were developed for the synthesis of 2-hydroxy-3-alkyl-2-phenyl-2,3-dihydroquinazolin4(1H)-one via catalytic carbonylation with molybdenum hexacarbonyl as an efficient carbonylating agent for the three-component reaction of isatoic anhydride, amine, iodobenzene. Mo(CO)6 is a solid carbon monoxide source. The quinazoli...

Read More
View All
×

You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.

If you wish to continue to this external website, click Proceed.

ProceedBack